When was Arcellx founded?

Arcellx was founded in 2014 and raised its 1st funding round 3 years after it was founded.

Where is Arcellx located?

Arcellx is headquartered in Rockville, United States.

Who is the current CEO of Arcellx?

David M Hilbert and Rami Elghandour s of Arcellx. David M Hilbert has also founded 1 company.

How many employees does Arcellx have?

As of Jun 30, 2026, the latest employee count at Arcellx is 219.

Is Arcellx a funded company?

Arcellx is a funded company, having raised a total of $248M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 2017.

How much is Arcellx worth?

The last known valuation of Arcellx was $***** as of Feb 23, 2026.

When was the latest funding round of Arcellx?

Arcellx's latest funding was a $***** Post IPO round on Jan 26, 2023, with participation from 0 investor.

What is the annual revenue of Arcellx?

Annual revenue of Arcellx is between $10M and $50M as on Dec 31, 2025

Where does Arcellx rank among its competitors?

Arcellx ranks 335th amongst 3373 active competitors, of which 1148 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of Arcellx?

Arcellx's top competitors include Jazz Pharmaceuticals, Biogen and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

Arcellx - 2026 Company Profile, Team, Funding, Competitors & Financials

Arcellx is an acquired company based in Rockville (United States), founded in 2014 by David M Hilbert. It operates as a Developer of T cell-mediated anti tumour therapy. Arcellx has raised $248M in funding from investors like Aju IB Investment, CAM Capital and Samsara BioCapital, with last known valuation of $*****. The company has 3373 active competitors, including 1148 funded and 804 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and Sana Biotechnology.

Company Details

Developer of T cell-mediated anti-tumour therapy. The company has developed its proprietary technology ARC-sparX platform used for the treatment of cancer and autoimmune disease. The ARC-T cells are engineered T-cells that bind to sparX proteins and helps to kill diseased cells. The company's products include CART-ddBCMA and ACLX-001 for multiple myeloma and ACLX-002 for AML. It is also developing therapeutics for solid tumours.

Website: arcellx.com
Social
Email ID: *****@arcellx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2014

Location

Rockville, United States

Stage

Acquired

Total Funding

$248M in 6 rounds

Latest Funding Round

Post IPO, Jan 26, 2023, $*****

Last Known Valuation

$***** as on Feb 23, 2026

Investors

Aju IB Investment & 25 more

Ranked

335^th among 3373 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

219 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3142 more

Exit Details

Acquired by Gilead (Feb 23, 2026)

View Arcellx's full profile

Arcellx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Arcellx, Inc. CIN: 1786205 , United States, Active	Dec 17, 2014	$10M - $50M (As on Dec 31, 2025)	161 (As on Dec 31, 2024)	-

Arcellx got acquired by Gilead on Feb 23, 2026.

Click here to take a look at Arcellx's acquisition in detail

Arcellx has raised a total funding of $248M over 6 rounds. Its first funding round was on Sep 2017. Arcellx has 25 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Arcellx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 26, 2023	7207127	Post IPO	2017363	2141195	1275180	7108852
Feb 27, 2022	6938259	Post IPO	4422093	7881660	4987198	1038831
Mar 26, 2021	8830212	Series C	3409230	5984920	Samsara BioCapital & 1 more	New Enterprise Associates & 13 more

Access funding benchmarks and valuations. Sign up today!

View details of Arcellx's funding rounds and investors

The founders of Arcellx is David M Hilbert. David M Hilbert and Rami Elghandour are the CEOs of Arcellx.

Here are the details of Arcellx's key team members:

David M Hilbert: Founder & Co-CEO of Arcellx.
Rami Elghandour: Co-CEO of Arcellx.

View details of Arcellx's Founder profiles and Board Members

Arcellx's employee count trend

Arcellx has 219 employees as of Jun 26. Here is Arcellx's employee count trend over the years:

Uncover Arcellx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Arcellx include Jazz Pharmaceuticals, Biogen and Sana Biotechnology. Here is the list of Top 10 competitors of Arcellx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
335th	Arcellx 2014, Rockville (United States), Acquired	Developer of T cell-mediated anti tumour therapy	$248M	CAM Capital, Novo Holdings & 24 others	57/100